Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Selecta Biosciences (SELB)

Selecta Biosciences (SELB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 136,766
  • Shares Outstanding, K 155,204
  • Annual Sales, $ 110,780 K
  • Annual Income, $ 35,380 K
  • 60-Month Beta 0.84
  • Price/Sales 1.34
  • Price/Cash Flow 9.91
  • Price/Book 2.07
Trade SELB with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.22
  • Most Recent Earnings $-0.07 on 08/17/23
  • Latest Earnings Date 11/16/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/23
See More
  • Average Estimate -0.06
  • Number of Estimates 2
  • High Estimate -0.03
  • Low Estimate -0.10
  • Prior Year -0.01
  • Growth Rate Est. (year over year) -500.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8100 +8.79%
on 11/13/23
1.3000 -32.22%
on 10/31/23
-0.1988 (-18.41%)
since 10/13/23
3-Month
0.8100 +8.79%
on 11/13/23
1.3000 -32.22%
on 10/31/23
-0.2188 (-19.89%)
since 08/11/23
52-Week
0.8100 +8.79%
on 11/13/23
1.9900 -55.72%
on 02/14/23
-0.6588 (-42.78%)
since 11/11/22

Most Recent Stories

More News
Selecta Biosciences, Inc. (SELB) Reports Q1 Loss, Misses Revenue Estimates

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -37.50% and 59.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

SELB : 0.8812 (-8.00%)
LVTX : 2.64 (-3.65%)
Cellarity Strengthens Executive Leadership Team

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are discovered, announced today the appointments of John Leaman, M.D., M.B.A., as Chief Financial Officer...

IMPL : 0.0400 (-27.27%)
SELB : 0.8812 (-8.00%)
MDGN : 5.57 (+3.15%)
DNLI : 14.96 (-3.86%)
EVLO : 0.0457 (+3.39%)
FHTX : 5.23 (+0.38%)
MRNA : 106.18 (-2.45%)
OMGA : 2.35 (+0.86%)
SANA : 8.50 (-0.93%)
MCRB : 0.7400 (+1.44%)
Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB

/PRNewswire/ -- Selecta Biosciences, Inc. (NASDAQ: SELB) and Sobi®, today announced positive topline results from the Phase 3 DISSOLVE I & II placebo...

SELB : 0.8812 (-8.00%)
Selecta Biosciences, Inc. (SELB) Reports Q4 Loss, Tops Revenue Estimates

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of 25% and 32.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

SELB : 0.8812 (-8.00%)
ARAV : 0.0401 (-13.39%)
Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease

/PRNewswire/ -- Selecta Biosciences, Inc. (NASDAQ: SELB, President and CEO: Carsten Brunn, Ph.D., "Selecta"), and Astellas Pharma Inc. (TSE: 4503, President...

SELB : 0.8812 (-8.00%)
Selecta Biosciences, Inc. (SELB) Reports Q3 Loss, Lags Revenue Estimates

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -200% and 37.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

SELB : 0.8812 (-8.00%)
WVE : 4.74 (-5.39%)
ChromaDex (CDXC) Reports Q3 Loss, Misses Revenue Estimates

ChromaDex (CDXC) delivered earnings and revenue surprises of 33.33% and 8.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CDXC : 3.39 (-0.29%)
SELB : 0.8812 (-8.00%)
Elevance Health's (ELV) Low-Cost MA Plans to Widen U.S. Base

Elevance Health (ELV) devises suitable Medicare Advantage plans containing supplemental benefits, which consumers can avail in the 2023 Annual Enrollment Period.

HUM : 311.41 (-1.45%)
KR : 55.91 (-0.43%)
SELB : 0.8812 (-8.00%)
ELV : 539.68 (+1.11%)
Selecta Biosciences, Inc. (SELB) Q2 Earnings and Revenues Surpass Estimates

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of 300% and 83.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

SELB : 0.8812 (-8.00%)
HGEN : 0.0002 (-84.62%)
Selecta Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

– Completed enrollment of DISSOLVE II, triggering a $10 million milestone payment obligation from Swedish Orphan Biovitrum AB (publ.) (Sobi); DISSOLVE I...

SELB : 0.8812 (-8.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and...

See More

Key Turning Points

3rd Resistance Point 1.0740
2nd Resistance Point 1.0069
1st Resistance Point 0.9441
Last Price 0.8812
1st Support Level 0.8142
2nd Support Level 0.7471
3rd Support Level 0.6843

See More

52-Week High 1.9900
Fibonacci 61.8% 1.5392
Fibonacci 50% 1.4000
Fibonacci 38.2% 1.2608
Last Price 0.8812
52-Week Low 0.8100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar